A study of pharmacokinetic properties of artemisinin combination therapy for malaria in specific populations

Sri Riyati Sugiarto

doi:10.26182/dy51-d824

A study of pharmacokinetic properties of artemisinin combination therapy for malaria in specific populations

Sri Riyati Sugiarto

UWA Medical School

Research output: Thesis › Doctoral Thesis

407 Downloads (Pure)

Abstract

Studies of the pharmacokinetic properties of artemisinin-lumefantrine, the recommended first-line treatment for malaria, were conducted in three special populations: Tanzanian children with sickle cell trait/disease, Sarawakian adults with Plasmodium knowlesi infections, and non-immune overweight/obese healthy volunteers. Plasma concentration profiles show that currently recommended artemisinin-lumefantrine dose regimens for adults and children are appropriate in these clinical situations. Due to the large number of knowlesi malaria cases in Malaysian Borneo, an epidemiological survey was performed at high-risk locations in West Kalimantan across the border in Indonesian Borneo. The lack of knowlesi malaria cases detected suggests unexpected geo-epidemiological differences between the two regions.

Original language	English
Qualification	Doctor of Philosophy
Awarding Institution	The University of Western Australia
Supervisors/Advisors	Davis, Timothy, Supervisor Davis, Wendy, Supervisor Salman, Sam, Supervisor Manning, Laurens, Supervisor
Award date	26 May 2023
DOIs	https://doi.org/10.26182/dy51-d824
Publication status	Unpublished - 2023

UN SDGs

This output contributes to the following UN Sustainable Development Goals (SDGs)

SDG 3 Good Health and Well-being

Access to Document

10.26182/dy51-d824

THESIS - DOCTOR OF PHILOSOPHY - SUGIARTO Sri Riyati - 2023 - Part 1
THESIS - DOCTOR OF PHILOSOPHY - SUGIARTO Sri Riyati - 2023 - Part 2
This work is protected by Copyright. You may print or download ONE copy of this document for the purpose of your own non-commercial research or study. Any other use requires permission from the copyright owner. The Copyright Act requires you to attribute any copyright works you quote or paraphrase.

A survey of simian Plasmodium infections in humans in West Kalimantan, Indonesia
Sugiarto, S. R., Natalia, D., Mohamad, D. S. A., Rosli, N., Davis, W. A., Baird, J. K., Singh, B., Elyazar, I., Divis, P. C. S. & Davis, T. M. E., Dec 2022, In: Scientific Reports. 12, 1, 18546.
Research output: Contribution to journal › Article › peer-review

Open Access
8 Link opens in a new tab Citations (Scopus)
Pharmacokinetic properties of the antimalarial combination therapy artemether–lumefantrine in normal-weight, overweight and obese healthy male adults
Sugiarto, S. R., Page-Sharp, M., Drinkwater, J. J., Davis, W. A., Salman, S. & Davis, T. M. E., Jan 2022, In: International Journal of Antimicrobial Agents. 59, 1, 106482.
Research output: Contribution to journal › Article › peer-review
3 Link opens in a new tab Citations (Scopus)
The effect of sickle cell genotype on the pharmacokinetic properties of artemether-lumefantrine in Tanzanian children
Sugiarto, S. R., Bwire, G. M., Moore, B. R., Page-Sharp, M., Manning, L., Batty, K. T., Minzi, O. M. S., Ngasala, B., Davis, T. M. E., Makani, J. & Salman, S., Aug 2022, In: International Journal for Parasitology: Drugs and Drug Resistance. 19, p. 31-39 9 p.
Research output: Contribution to journal › Article › peer-review

Open Access

Cite this

@phdthesis{62b3e2b3e6b84867a8e708a8c77710e3,

title = "A study of pharmacokinetic properties of artemisinin combination therapy for malaria in specific populations",

abstract = "Studies of the pharmacokinetic properties of artemisinin-lumefantrine, the recommended first-line treatment for malaria, were conducted in three special populations: Tanzanian children with sickle cell trait/disease, Sarawakian adults with Plasmodium knowlesi infections, and non-immune overweight/obese healthy volunteers. Plasma concentration profiles show that currently recommended artemisinin-lumefantrine dose regimens for adults and children are appropriate in these clinical situations. Due to the large number of knowlesi malaria cases in Malaysian Borneo, an epidemiological survey was performed at high-risk locations in West Kalimantan across the border in Indonesian Borneo. The lack of knowlesi malaria cases detected suggests unexpected geo-epidemiological differences between the two regions.",

keywords = "Malaria treatment, Artemether-lumefantrine, Pharmacokinetic of sickle cell disease and artemisinin combination, Plasmodium knowlesi, Plasmodium in Kalimantan, Pharmacokinetic in obesity",

author = "Sugiarto, \{Sri Riyati\}",

year = "2023",

doi = "10.26182/dy51-d824",

language = "English",

school = "The University of Western Australia",

}

TY - BOOK

T1 - A study of pharmacokinetic properties of artemisinin combination therapy for malaria in specific populations

AU - Sugiarto, Sri Riyati

PY - 2023

Y1 - 2023

N2 - Studies of the pharmacokinetic properties of artemisinin-lumefantrine, the recommended first-line treatment for malaria, were conducted in three special populations: Tanzanian children with sickle cell trait/disease, Sarawakian adults with Plasmodium knowlesi infections, and non-immune overweight/obese healthy volunteers. Plasma concentration profiles show that currently recommended artemisinin-lumefantrine dose regimens for adults and children are appropriate in these clinical situations. Due to the large number of knowlesi malaria cases in Malaysian Borneo, an epidemiological survey was performed at high-risk locations in West Kalimantan across the border in Indonesian Borneo. The lack of knowlesi malaria cases detected suggests unexpected geo-epidemiological differences between the two regions.

AB - Studies of the pharmacokinetic properties of artemisinin-lumefantrine, the recommended first-line treatment for malaria, were conducted in three special populations: Tanzanian children with sickle cell trait/disease, Sarawakian adults with Plasmodium knowlesi infections, and non-immune overweight/obese healthy volunteers. Plasma concentration profiles show that currently recommended artemisinin-lumefantrine dose regimens for adults and children are appropriate in these clinical situations. Due to the large number of knowlesi malaria cases in Malaysian Borneo, an epidemiological survey was performed at high-risk locations in West Kalimantan across the border in Indonesian Borneo. The lack of knowlesi malaria cases detected suggests unexpected geo-epidemiological differences between the two regions.

KW - Malaria treatment

KW - Artemether-lumefantrine

KW - Pharmacokinetic of sickle cell disease and artemisinin combination

KW - Plasmodium knowlesi

KW - Plasmodium in Kalimantan

KW - Pharmacokinetic in obesity

U2 - 10.26182/dy51-d824

DO - 10.26182/dy51-d824

M3 - Doctoral Thesis

ER -

A study of pharmacokinetic properties of artemisinin combination therapy for malaria in specific populations

Abstract

UN SDGs

Access to Document

Fingerprint

Research output

A survey of simian Plasmodium infections in humans in West Kalimantan, Indonesia

Pharmacokinetic properties of the antimalarial combination therapy artemether–lumefantrine in normal-weight, overweight and obese healthy male adults

The effect of sickle cell genotype on the pharmacokinetic properties of artemether-lumefantrine in Tanzanian children

Cite this